Validation of psoriasis disability index (PDI) questionnaire Sinhala version

2021 ◽  
Author(s):  
Achala Liyanage ◽  
G. Liyanage ◽  
V. De Silva ◽  
J. Akarawita ◽  
C. Gunasekera ◽  
...  
Keyword(s):  
Psoriasis Disability Index

ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study

2008 ◽  
Vol 12 (6) ◽  
pp. 268-275 ◽  
Author(s):  
Aditya K. Gupta ◽  
Richard G. Langley ◽  
Charles Lynde ◽  
Kirk Barber ◽  
Wayne Gulliver ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Life Quality ◽  
Skin Condition ◽  
Controlled Study ◽  
Double Blind ◽  
Plaque Type ◽  
Psoriasis Disability Index ◽  
Stable Plaque

Background: Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported. Objective: The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis. Methods: A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d ( n = 77) or 1.5 mg/kg/d ( n = 83) compared with placebo ( n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales. Results: ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo ( p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group ( p < .05). Conclusions: ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.

scholarly journals PEE4: THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX

2001 ◽  
Vol 4 (2) ◽  
pp. 119
Author(s):  
A Finlay ◽  
M Corvest ◽  
P Lefrançois ◽  
C Taieb
Keyword(s):  
French Version ◽  
Psoriasis Disability Index

scholarly journals The Turkish Version of the Psoriasis Disability Index: A Validation and Reliability Study

TURKDERM ◽  
2011 ◽  
Vol 45 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Neslihan Fişek ◽  
Gonca Gökdemir ◽  
Adem Köşlü ◽  
Günay Can
Keyword(s):  
Turkish Version ◽  
Reliability Study ◽  
Psoriasis Disability Index

scholarly journals Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study

2020 ◽  
Vol 6 (4) ◽  
pp. 505
Author(s):  
Ömer Kutlu ◽  
Hatice M. Eksioglu
Keyword(s):  
Metabolic Syndrome ◽  
Treatment Response ◽  
Life Quality ◽  
Severity Index ◽  
Potential Effect ◽  
Effective Treatment Option ◽  
Plaque Type ◽  
Lower Response Rate ◽  
Psoriasis Disability Index ◽  
The Mean

<p class="abstract"><strong>Background:</strong> Ustekinumab is a biological agent used in the treatment of psoriasis. This study evaluated the treatment response of psoriasis patients who received ustekinumab.</p><p class="abstract"><strong>Methods:</strong> The study included nine patients with plaque-type psoriasis who received ustekinumab treatment. Clinical response of all patients was evaluated with psoriasis area and severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) at 0, 4, 16 and 28 weeks. The patients were also evaluated for metabolic syndrome and its effect on treatment response.<strong></strong></p><p class="abstract"><strong>Results:</strong> A total of five male and four female patients with psoriasis vulgaris were included in the study. At the end of 28th weeks, 55% of the patients reached PASI 75 score. The mean PASI scores of the patients at weeks 0, 4, 16, 26 and 28 were 36.98±12.28, 8.86±9.06, 9.52±11.55, 3.55±3.61 and 6.98±6.40, respectively. Although not statistically significant, at the 28th weeks, the mean PASI, DLQI and PDI values of the patients with metabolic syndrome were higher than those without metabolic syndrome (p=0.505, p=0.314, p=0.786, respectively).</p><p class="abstract"><strong>Conclusions:</strong> Ustekinumab is an effective treatment option for patients with psoriasis who resistant to conventional and biological treatments. In resistant cases to the ustekinumab, the routine treatment interval should be reduced. Psoriasis patients with accompanying metabolic syndrome may have a lower response rate than those without metabolic syndrome to biological agents.</p>

Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis

1990 ◽  
Vol 123 (6) ◽  
pp. 751-756 ◽  
Author(s):  
A.Y. FINLAY ◽  
G.K. KHAN ◽  
D.K. LUSCOMBE ◽  
M.S. SALEK
Keyword(s):  
Sickness Impact Profile ◽  
Psoriasis Disability Index

scholarly journals A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index

2020 ◽  
Vol 23 (7) ◽  
pp. 737-743
Author(s):  
Juan Su ◽  
Tong Liu ◽  
Shunping Li ◽  
Yue Zhao ◽  
Yehong Kuang
Keyword(s):  
Mainland China ◽  
Mapping Study ◽  
Psoriasis Disability Index ◽  
Utility Scores

scholarly journals Comparação entre questionários de qualidade de vida e sua correlação com a evolução clínica de pacientes com psoríase

2011 ◽  
Vol 86 (1) ◽  
pp. 45-49 ◽  
Author(s):  
Rafael Augusto Tamasauskas Torres ◽  
Suze Aparecida da Silva ◽  
Renata Ferreira Magalhães ◽  
André Moreno Morcillo ◽  
Paulo Eduardo Neves Ferreira Velho
Keyword(s):  
Quality Index ◽  
Life Quality ◽  
Psoriasis Disability Index ◽  
Life Quality Index

FUNDAMENTO: A psoríase é uma dermatose inflamatória crônica caracterizada por lesões eritemato-descamativas que atingem extensas áreas da pele, comprometendo a qualidade de vida dos pacientes por interferir na sua vida pessoal, no relacionamento social e nas atividades diárias. O tratamento permite um bom controle, mas a impressão do paciente, quase sempre, é pouco valorizada. OBJETIVOS: Avaliar a qualidade de vida de pacientes psoriáticos, verificar se há correlação desta com melhoras clínicas e se há equivalência entre dois questionários de qualidade de vida. MÉTODOS: Foram incluídos no estudo pacientes maiores de 18 anos que estavam no início ou troca de tratamento no ambulatório de psoríase do Hospital de Clínicas da Unicamp. Eles responderam dois questionários de qualidade de vida (Psoriasis Disability Index e Dermatological Life Quality Index), até completar 180 atendimentos, para avaliar se haveria correlação entre os questionários. Receberam também um índice clínico (Índice de Área e de Severidade da Psoríase) no tempo inicial da pesquisa e nos retornos subsequentes. RESULTADOS: A pesquisa foi realizada com 138 pacientes (76 homens, idade média de 50 anos). Observou-se correlação entre os questionários aplicados e o índice clínico, mostrando que alterações clínicas se refletem na qualidade de vida, e que há equivalência entre os questionários. CONCLUSÃO: Constatou-se que a maioria dos pacientes atendidos no ambulatório tem apresentado melhora clínica e da qualidade de vida e que há equivalência entre os questionários de qualidade de vida.

scholarly journals Psoriasis disability index: The role of sociodemographic and clinical variables

TURKDERM ◽  
2014 ◽  
Vol 48 (4) ◽  
pp. 187-192 ◽  
Author(s):  
Sevgi Akarsu ◽  
Şebnem Aktan ◽  
Melda Demirtaşoğlu ◽  
Ayşe Şebnem Özkan
Keyword(s):  
Clinical Variables ◽  
Psoriasis Disability Index
Sign in / Sign up

Export Citation Format

Share Document